Novo Nordisk Capital Markets Day Weekend Preview: CEO Mike Doustdar Frames Monday London Reset Around 'Obesity Is Not a Zero-Sum Game' and 'The Novo Way' Culture Framework
Weekend previews of the Monday September 21, 2026 Novo Capital Markets Day in London (webcast live from 09:00 BST / 10:00 CET, running to 15:30 BST / 16:30 CET) landed Saturday and Sunday framing CEO Mike Doustdar's most direct commentary to date on the semaglutide-vs-tirzepatide franchise dynamic. In a Reuters interview released Friday September 18, Doustdar characterized the obesity market as not a 'zero-sum game' as patients 'crave optionality,' rejecting the Morgan Stanley Underweight thesis (September 11 downgrade, DKK 250 target) that Wegovy's U.S. share erosion is structural. Doustdar's 'Novo Way' culture framework announced with the September 14 rebrand emphasizes customer focus, competitiveness, clarity, and care. Sell-side previews (TIKR, Bloomberg, Kontra Invest, TradingKey) frame CMD priorities as: managing the 2031 semaglutide loss of exclusivity, U.S. Wegovy pill script trajectory (>5 million total prescriptions as of August), the CagriSema U.S. obesity decision path (late 2026), the ziltivekimab HERMES/ATHENA terminations, the $1.4 billion Orbis Medicines Sept 17 macrocycle deal, and the Sept 16 Anthropic Claude Science R&D collaboration. NVO shares closed Friday at $42.97 (-0.23% weekly).